Drug Eruption and Interactions - PHARMACEUTICAL REVIEW

318 LAMOTRIGINE
(2003): Naisbitt DJ+, J Allergy Clin Immunol 111(6), 1393
(2003): Vieta E+, Actas Esp Psiquiatr 31(2), 65
(2002): Anderson GD, Epilepsia 43(Suppl 3), 53 (10–20%)
(2002): Bowden CL, Expert Opin Pharmacother 3(10), 1513
(2002): Calabrese JR+, J Clin Psychiatry 63(11), 1012 (8.3%)
(2002): Huang CW+, KaohsiungJMedSci18(11), 566
(2002): Hurley SC, Ann Pharmacother 36(5), 860
(2002): Labiner DM, J Clin Psychiatry 63(11), 1010
(2001): Eisenberg E+, Neurology 57, 505
(2000): Besag FM+, Seizure 9, 282
(2000): Husain AM+, South Med J 93, 335
(2000): Jurynczyk J+, Neurol Neurochir Pol (Polish) 34, 43
(2000): Messenheimer JA+, Drug Saf 22, 303
(2000): Messenheimer JA+, Epilepsia 41, 488
(2000): Parmeggiani L+, J Child Neurol 15, 15
(1999): Faught E+, Epilepsia 40, 1135
(1999): Gericke CA+, Epileptic Disord 1, 159
(1999): Guberman AH+, Epilepsia 40, 985
(1999): Matsuo F, Epilepsia 40, S30
(1998): Buzan RD+, J Clin Psychiatry 59, 87 (re-challenged)
(1998): Messenheimer JA, Can J Neurol Sci 25, S14
(1997): Mackay FJ+, Epilepsia 38, 881
Raynaud’s phenomenon
(2000): Sarzi-Puttini P+, Lupus 9(7), 555
Stevens–Johnson syndrome (1–10%)
(2007): Hilas O+, Am J Health Syst Pharm 64(3), 273
(2007): Kocak S+, Am J Clin Dermatol 8(2), 107 (with valproic
acid)
(2006): Hirsch LJ+, Epilepsia 47(2), 318 (1 case)
(2006): Wolf R+, Int Arch Allergy Immunol 141(3), 308
(2005): Fein JD+, NEnglJMed352(16), 1696
(2005): Mockenhaupt M+, Neurology 64(7), 1134
(2003): Feliciani C+, Int J Immunopathol Pharmacol 16(1), 89
(2002): Bowden CL, Expert Opin Pharmacother 3(10), 1513
(2002): Calabrese JR+, J Clin Psychiatry 63(11), 1012 (1 case)
(2002): Huang CW+, KaohsiungJMedSci18(11), 566
(2001): Hebert AA+, J Clin Psychiatry 62(suppl 14), 22 (~10%)
(2000): Popescu C, Bucharest, Romania (from Internet)
(observation)
(2000): Yalcin B+, JAmAcadDermatol43, 898 (with valproic
acid)
(1999): Bocquet H+, Ann Dermatol Venereol (French) 126, 46
(1999): Borowitz SM, Pediatric Pharmacotherapy 5, 3
(1999): Guberman AH+, Epilepsia 40, 985
(1999): Rzany B+, Lancet 353, 2190
(1998): Drugs and Therapy Perspectives 11, 11
(1998): Messenheimer J+, Drug Saf 18(4), 281
(1998): Schlienger RG+, Epilepsia 39, S22
(1998): Zachariae CO+, Ugeskr Laeger (Danish) 160, 6656
(1997): Australian Adverse Drug Reactions Bulletin 16(1), February
(1997): Knowles S+, Curr Opin Pediatr 9(4), 388
(1997): Mackay FJ+, Epilepsia 38, 881
(1997): Sachs B+, Dermatology 195, 60
(1996): Dooley J+, Neurology 46, 240 (7%)
(1995): Campistol J+, Rev Neurol (Spanish) 23, 1236
(1995): Duval X+, Lancet 345, 1301
Toxic epidermal necrolysis
(2006): Varghese SP+, Pharmacotherapy 26(5), 699
(2005): Mansouri P+, Arch Dermatol 141(6), 788 (with
carbamazepine)
(2005): Rodriguez-Blanco I+, Actas Dermosifiliogr 96(2), 116
(2004): Haefliger IO+, Klin Monatsbl Augenheilkd 221(5), 395
(2004): Hashim N+, Acta Derm Venereol 84(1), 90 (with valproic
acid)
(2004): Sladden M+, Aust Fam Physician 33(10), 829
(2003): Clennett S+, J Wound Care 12(4), 151
(2003): Feliciani C+, Int J Immunopathol Pharmacol 16(1), 89
(2003): Mayorga C+, Ann Allergy Asthma Immunol 91(1), 86
(2003): Sogut A+, Acta Neurol Belg 103(2), 95
(2002): Wirtzer A, Sherman Oaks, CA (from Internet)
(observation)
(2001): Hebert AA+, J Clin Psychiatry 62(suppl 14), 22 (~1%)
(2001): Wensween CA+, Ned Tijdschr Geneeskd 145(31), 1525
(2000): Bhushan M+, Clin Exp Dermatol 25, 349
(2000): Fernandez-Calvo C+, Rev Neurol 31(12), 1162
(1999): Actas Dermosifiliogr (Spanish) 90, 612
(1999): Bocquet H+, Ann Dermatol Venereol (French) 126, 46
(1999): Borowitz SM, Pediatric Pharmacotherapy 5, 3
(1999): Rzany B+, Lancet 353, 2190
(1998): Drugs and Therapy Perspectives 11, 11
(1998): Page RL+, Pharmacotherapy 18, 392 (fatal)
(1998): Schlienger RG+, Epilepsia 39, S22
(1998): Zachariae CO+, Ugeskr Laeger (Danish) 160, 6656
(1997): Australian Adverse Drug Reactions Bulletin 16(1), February
(1997): Chaffin JJ+, Ann Pharmacother 31, 720 (suspected)
(1997): Fogh K+, Seizure 6, 63
(1997): Knowles S+, Curr Opin Pediatr 9(4), 388
(1997): Vukelic D+, Dermatology 195, 307
(1996): Sachs B+, Lancet 348, 1597
(1996): Sullivan JR+, Australas J Dermatol 37, 208
(1996): Wadelius M+, Lancet 348, 1041
(1995): Duval X+, Lancet 345, 1301
(1995): Sterker M+, Int J Clin Pharmacol Ther 33, 595
Urticaria (